ImpriMed, a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, announced the close of a $2...
Ribbon cutting and commissioning of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing facility that expands capacity by approxi...
– PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial – – Confirmatory trial found PADCEV plus pembrolizumab nearly ...
The study by YolTech is a single-arm, open-label, dose-escalation clinical trial (Clinicaltrials.gov: NCT06082050). This trial's primary objectives are to ...
Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1 Milestone highlights Biogen’s growing portfolio in...
Biolojic’s BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases....
In the updated NDRL, TYVYT® expands its coverage to the seventh new indication for the treatment of patients with epidermal growth factor receptor (EGF...
Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrates statistically significant and clinically meaningful improvement in progression-free survival compa...
In 2016, IMIDomics entered into a strategic partnership with BMS to harness their unique clinical and molecular database, and multidimensional analysis con...
Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales mile...
Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inh...
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the...
-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – -...
Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks While most common adv...
© 2024 Biopharma Boardroom. All Rights Reserved.
